Implications of the CANVAS Study in Reducing Cardiovascular Outcomes

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Cardiovascular Outcome Event Trials (CVOTs) in type 2 diabetes mellitus (T2DM) have highlighted the cardiovascular benefits of sodium glucose transporter 2 inhibitors (SGLT2i).
• These benefits, including reduced major adverse cardiovascular events (MACE) and cardiovascular mortality, appear independent of glucose-lowering mechanisms.
• Biologically plausible theories support the macrovascular benefits observed with SGLT2i.

Purpose of the Study:

• To review and discuss the findings of the CANVAS program, a unique analysis of two aggregated cohorts treated with canagliflozin.
• To compare the results of the CANVAS program with other relevant trials, such as EMPA-REG OUTCOMES and CVD-REAL.

Main Methods:

• Analysis of two aggregated cohorts from the CANVAS program with varying durations of canagliflozin exposure.
• Comparison of CANVAS program results with EMPA-REG OUTCOMES and CVD-REAL, considering population characteristics and outcomes.

Main Results:

• The CANVAS program showed a 14% reduction in the primary MACE composite, although individual components were not significantly different from placebo.
• An initial analysis indicated a reno-protective effect of canagliflozin.
• CANVAS results showed similarities and differences compared to EMPA-REG OUTCOMES, particularly in cardiovascular mortality and adverse event profiles, potentially due to population risk profiles or drug-specific effects.

Conclusions:

• The CANVAS program provides valuable insights into the cardiovascular and renal effects of SGLT2 inhibitors in T2DM patients.
• Comparisons suggest that CANVAS findings may be generalizable to a broader population than initially studied.
• Further research is warranted to elucidate drug-specific mechanisms and optimize SGLT2i use for cardiovascular risk reduction in T2DM.